Lack of autologous neutralizing antibody to human immunodeficiency virus type 1 (HIV-1) and macrophage tropism are associated with mother-to-infant transmission

Journal of Infectious Diseases

Volumn 180, Issue 2, 1999, Pages 344-350

  Lathey, Janet L ^a   Tsou, Jeff ^a   Brinker, Karen ^a   Hsia, Karen ^a   Meyer III, William A ^b   Spector, Stephen A ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b QUEST DIAGNOSTICS NICHOLS INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

NEUTRALIZING ANTIBODY;

ANTIGEN PRESENTATION; ARTICLE; CLINICAL ARTICLE; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MONONUCLEAR CELL; PRIORITY JOURNAL; VERTICAL TRANSMISSION; VIROGENESIS; VIRUS LOAD; VIRUS REPLICATION; VIRUS TRANSMISSION;

DISEASE TRANSMISSION, VERTICAL; FEMALE; GIANT CELLS; HIV ANTIBODIES; HIV CORE PROTEIN P24; HIV INFECTIONS; HIV-1; HUMANS; LEUKOCYTES, MONONUCLEAR; MACROPHAGES; NEUTRALIZATION TESTS; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS; RNA, VIRAL; VIRAL LOAD; VIREMIA;

EID: 0033504524     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/314886     Document Type: Article

References (24)

1. 1. Bryson YJ. Perinatal HIV-1 transmission: recent advances and therapeutic interventions. AIDS 1996; 10 (Suppl. 3):S33-42.
2. 2. Connor EM, Sperling RS, Gelber R, et al. Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. N Engl J Med 1994;331:1173-80.
3. 3. Sperling RS, Shapiro DE, Coombs RW, et al. Maternal viral load, zidovudine treatment, and the risk of transmission of human immunodeficiency virus type 1 from mother to infant. N Engl J Med 1996;335:1621-9.
4. 4. Dickover RE, Garratty EM, Herman SA, et al. Identification of levels of maternal HIV-1 RNA associated with risk of perinatal transmission: effect of maternal zidovudine treatment on viral load. JAMA 1996;275:599-605.
5. 5. Cao Y, Krogstad P, Korber BT, et al. Maternal HIV-1 viral load and vertical transmission of infection: the Ariel Project for the prevention of HIV transmission from mother to infant. Nat Med 1997;3:549-52.
6. 6. Fang G, Burger H, Grimson R, et al. Maternal plasma human immunodeficiency virus type 1 RNA level: a determinant and projected threshold for mother-to-child transmission. Proc Natl Acad Sci USA 1995;92: 12100-4.
7. 7. Mayaux MJ, Dussaix E, Isopet J, et al. Maternal virus load during pregnancy and mother to child transmission of human immunodeficiency virus type 1: the French Perinatal Cohort studies. J Infect Dis 1997;175:172-5.
8. 8. Weiser B, Nachman S, Tropper P, et al. Quantitation of human immunodeficiency virus type 1 during pregnancy: relationship of viral titer to mother-to-ehild transmission and stability of viral load. Proc Natl Acad Sci USA 1994;91:8037-41.
9. 9. Japour A, Fiscus S, Arduino JM, et al. Standardized microtiter assay for determination of syncytium-inducing phenotypes of clinical human immunodeficiency virus type 1 isolates. J Clin Microbiol 1994;32:2291-4.
10. 10. US Department of Health and Human Services. ACTG virology manual for HIV laboratories, NIH publication 94-3828. 1994; SIA-1-3.
11. 11. Lathey JL, Hughes MD, Fiscus SA, et al. Variability and prognostic values of virologic and CD4 cell measures in human immunodeficiency virus type 1 infected patients with 200-500 CD4 cells/mm3 (ACTG 175). J Infect Dis 1998;177:617-24.
12. 12. Myers LE, McQuay LJ, Hollinger FB. Dilution assay statistics. J Clin Microbiol 1994;32:732-9.
13. 13. Lathey JL, Spector SA. Unrestricted replication of human cytomegalovirus in hydrocortisone-treated macrophages. J Virol 1991;65:6371-5.
14. 14. Gillis PN, Lalhey PN, Spector SA. Replication of macrophage-tropic and T-cell tropic strains of human immunodeficiency virus type 1 is augmented by macrophage-endothelial cell contact.. J Virol 1995;69:2133-9.
15. 15. Roben O, Moore JP, Thali M, Sodroski J, Barbas CF III, Burton DR. Recognition properties of a panel of human recombinant Fab fragments to the CD4 binding site of GP120 that show differing abilities to neutralize human immunodeficiency virus type 1. J Virol 1994;68:4821-8.
16. 16. Scarlatti G, Albert J, Rossi P, et al. Mother-to-child transmission of human immunodeficiency virus type 1: correlation with neutralizing antibodies against primary isolates. J Infect Dis 1993;168:207-10.
17. 17. Kliks S, Wara DW, Landers DV, Levy JA. Features of HIV-1 that could influence maternal-child transmission. JAMA 1994;272:467-74.
18. 18. Husson RN, Lan Y, Kojima E, Venzon D, Mitsuya H, McIntosh K. Vertical transmission of human immunodeficiency virus type 1: autologous neutralizing antibody, virus load, and virus phenotype. J Pediatr 1995;126: 865-71.
19. 19. Mabondzo A, Narwa R, Roques P, et al. Lack of correlation between vertical transmission of HIV-1 and maternal antibody titers against autologous virus in human monocyte-derived macrophages. J Acquir Immune Defic Syndr Hum Retrovirol 1998;17:92-4.
20. 20. Ometto L, Zanotto C, Maccabruni A, et al. Viral phenotype and host-cell susceptibility to HIV-1 infection as risk factors for mother-to-child HIV-1 transmission. AIDS 1995;9:427-34.
21. 21. Scarlatti G, Hodara V, Rossi P, et al. Transmission of human immunodeficiency virus type 1 (HIV-1) from mother to child correlates with viral phenotype. Virology 1993;197:624-9.
22. 22. Lewis SH, Reynolds-Kohler C, Fox HE, Nelson JA. HIV-1 in trophoblastic and villous Hofbauer cells, and haematological precursors in eight-week fetuses. Lancet 1990;335:565-8.
23. 23. Reinhardt PP, Reinhardt B, Lathey JL, Spector SA. Human cord blood mononuclear cells are preferentially infected by non-syncytium-inducung, macrophage-tropic human immunodeficiency virus type 1 isolates. J Clin Microbiol 1995;33:292-7.
24. 24. Spencer LT, Ogino MT, Dankner WM, Spector SA. Clinical significance of human immunodeficiency virus type 1 phenotypes in infected children. J Infect Dis 1994;169:491-51.